Primary prophylaxis of variceal hemorrhage: A randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate

被引:121
作者
Lui, HF
Stanley, AJ
Forrest, EH
Jalan, R
Hislop, WS
Mills, PR
Finlayson, NDC
MacGilchrist, AJ
Hayes, PC
机构
[1] Gartnavel Royal Hosp, Glasgow, Lanark, Scotland
[2] Royal Alexandra Hosp, Paisley, Renfrew, Scotland
[3] Royal Infirm Edinburgh NHS Trust, Ctr Liver & Digest Disorders, Edinburgh, Midlothian, Scotland
关键词
D O I
10.1053/gast.2002.35385
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: This randomized controlled trial compared variceal band ligation (VBL), propranolol (PPL), and isosorbide-5-mononitrate (ISMN) in the prevention of first esophageal variceal bleed. Methods: Over a 6-year period, 172 patients with cirrhosis, grade II or III esophageal varices that had never bled, were recruited; 44 into VBL, 66 into PPL, and 62 into ISMN. Baseline patient characteristics: age, 55 +/- 11 years; Child-Pugh score, 8 +/- 2; 65% alcohol-induced cirrhosis; follow-up period, 19.7 +/- 17.6 months (range, 0.13-72.1 months), were comparable in the 3 groups. Results: On intention-to-treat analysis, variceal bleeding occurred in 7% of patients randomized to VBL, :14% to PPL, and 23% to ISMN. The 2-year actuarial risks for first variceal bleed were 6.2% (95% confidence interval [CI], 0.0%-15.0%) for VBL, 19.4% (95% CI, 0.1%-32.4%) for PPL, and 27.7% (95% CI, 14.2%-41.2%) for ISMN. A significant number of patients reported side effects with drug treatment (45% PPL and 42% ISMN vs. 2% VBL; P = 0.00), resulting in withdrawal from treatment in 30% of PPL and 21% of ISMN patients. There were no statistically significant differences in mortality rates in the 3 groups. In as-treated analysis, there was a statistically significant difference in actuarial risk for bleeding at 2 years between VBL and ISMN (7.5%, 95% CI, 2.5%-10.6% vs. 33.0%, 95% CI, 15%-49%, respectively, log rank test P = 0.03) but not between VBL and PPL. Conclusions: VBL was equivalent to PPL and superior to ISMN in preventing first variceal bleed. The side-effect profile for pharmacotherapy was considerable.
引用
收藏
页码:735 / 744
页数:10
相关论文
共 34 条
[1]   PREVENTIVE THERAPY OF 1ST GASTROINTESTINAL-BLEEDING IN PATIENTS WITH CIRRHOSIS - RESULTS OF A CONTROLLED TRIAL COMPARING PROPRANOLOL, ENDOSCOPIC SCLEROTHERAPY AND PLACEBO [J].
ANDREANI, T ;
POUPON, RE ;
BALKAU, BJ ;
TRINCHET, JC ;
GRANGE, JD ;
PEIGNEY, N ;
BEAUGRAND, M ;
POUPON, R .
HEPATOLOGY, 1990, 12 (06) :1413-1419
[2]   Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis [J].
Angelico, M ;
Carli, L ;
Piat, C ;
Gentile, S ;
Capocaccia, L .
GASTROENTEROLOGY, 1997, 113 (05) :1632-1639
[3]   RECOMMENDATIONS FOR STANDARDS OF SEDATION AND PATIENT MONITORING DURING GASTROINTESTINAL ENDOSCOPY [J].
BELL, GD ;
MCCLOY, RF ;
CHARLTON, JE ;
CAMPBELL, D ;
DENT, NA ;
GEAR, MWL ;
LOGAN, RFA ;
SWAN, CHJ .
GUT, 1991, 32 (07) :823-827
[4]  
BENDSTEN F, 1991, HEPATOLOGY, V14, P1016
[5]   Primary prevention of bleeding from esophageal varices [J].
Burroughs, AK ;
Patch, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (13) :1033-1035
[6]   Pharmacological treatment of portal hypertension: An evidence-based approach [J].
D'Amico, G ;
Pagliaro, L ;
Bosch, J .
SEMINARS IN LIVER DISEASE, 1999, 19 (04) :475-505
[7]   Endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleed: Preliminary report of a randomized controlled trial [J].
De, BK ;
Ghoshal, UC ;
Das, T ;
Santra, A ;
Biswas, PK .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1999, 14 (03) :220-224
[8]   DEFINITIONS, METHODOLOGY AND THERAPEUTIC STRATEGIES IN PORTAL-HYPERTENSION - A CONSENSUS DEVELOPMENT WORKSHOP, BAVENO, LAKE MAGGIORE, ITALY, APRIL 5 AND 6, 1990 [J].
DEFRANCHIS, R ;
PASCAL, JP ;
ANCONA, E ;
BURROUGHS, AK ;
HENDERSON, M ;
FLEIG, W ;
GROSZMANN, R ;
BOSCH, J ;
SAUERBRUCH, T ;
SOEDERLUND, C ;
LEBREC, D ;
SOERENSEN, TIA ;
PAGLIARO ;
ALEXANDRINO, P ;
ARCIDIACONO, R ;
BATTAGLIA, G ;
BOLONDI, L ;
CALES, P ;
CESTARI, L ;
COSENTINO, F ;
CURZIO, M ;
DAMICO, G ;
GERTSCH, P ;
GERUNDA, G ;
KREJS, G ;
FACCIOLI, AM ;
MINOLI, G ;
MOELLER, S ;
NEVENS, F ;
POMIERLAYRARGUES, G ;
PRIMIGNANI, M ;
SABBA, C ;
SPINA, G ;
STARITZ, M ;
TINE, F ;
VANBUUREN, HR ;
WESTABY, D ;
ZIPARO, V .
JOURNAL OF HEPATOLOGY, 1992, 15 (1-2) :256-261
[9]   ENHANCEMENT OF PORTAL PRESSURE REDUCTION BY THE ASSOCIATION OF ISOSORBIDE-5-MONONITRATE TO PROPRANOLOL ADMINISTRATION IN PATIENTS WITH CIRRHOSIS [J].
GARCIAPAGAN, JC ;
NAVASA, M ;
BOSCH, J ;
BRU, C ;
PIZCUETA, P ;
RODES, J .
HEPATOLOGY, 1990, 11 (02) :230-238
[10]   SHORT-TERM EFFECTS OF PROPRANOLOL ON PORTAL VENOUS-PRESSURE [J].
GARCIATSAO, G ;
GRACE, ND ;
GROSZMANN, RJ ;
CONN, HO ;
BERMANN, MM ;
PATRICK, MJC ;
MORSE, SS ;
ALBERTS, JL .
HEPATOLOGY, 1986, 6 (01) :101-106